Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Autor: Knop FK; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Herlev, Denmark. Electronic address: filip.krag.knop.01@regionh.dk., Aroda VR; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., do Vale RD; Novo Nordisk, Søborg, Denmark., Holst-Hansen T; Novo Nordisk, Søborg, Denmark., Laursen PN; Novo Nordisk, Søborg, Denmark., Rosenstock J; Velocity Clinical Research at Medical City, Dallas, TX, USA., Rubino DM; Washington Center for Weight Management and Research, Arlington, VA, USA., Garvey WT; Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.

Publikováno v: Lancet (London, England) [Lancet] 2023 Aug 26; Vol. 402 (10403), pp. 705-719. Date of Electronic Publication: 2023 Jun 26.